Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02189629 · ClinicalTrials.gov registry record · Phase 3
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
A Phase 3 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
NCT02189629 is a Phase 3 study that has completed, run by Galderma R&D. The registered enrollment target is 453 participants.
The verdict
NCT02189629, a Phase 3 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
Study Summary
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
Interventions
- DRUG CD5789 (trifarotene)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2015-02-23 |
| Est. Completion | 2017-02-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02189629
The ClinicalTrials.gov registry entry for NCT02189629 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD5789 (trifarotene) is the first listed.
NCT02189629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02189629 about?
NCT02189629 is a clinical study titled "CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris". Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
What is the current status of trial NCT02189629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2015-02-23. Estimated completion is 2017-02-23.
What interventions are being tested in trial NCT02189629?
The interventions under investigation include: CD5789 (trifarotene) (DRUG).
Who is sponsoring clinical trial NCT02189629?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.